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The Jefferson Familial Colorectal Cancer Registry  
Colorectal cancer is the second most common form of cancer in industrialized 
nations, accounting for approximately 11% of new cancer cases and 10% of cancer 
deaths. In 1998 there will be an estimated 131,600 new cases of colorectal cancer 
and 56,500 deaths from the disease in the United States. Studies indicate that early 
detection and intervention significantly decreases the morbidity and mortality of 
colorectal cancer 1.
Recognizing that family history inheritance plays an important role in colorectal 
cancer,2 the Jefferson Familial Polyposis Registry was formed in the mid-1980s. In 
1996, as part of the multidisciplinary approach to the prevention, diagnosis and 
treatment of colorectal cancer, the former Jefferson Familial Polyposis Registry 
expanded its the scope to include individuals diagnosed with cancer at a young age 
as well as those with a significant family history. The Jefferson Familial Colorectal 
Cancer Registry (the Registry) provides the critical link between the physicians who 
diagnose and treat colorectal cancer, and the physicians and scientists who study the 
molecular basis of the disease.  
 
Participation in the Registry enables a patient to know his/her genetic profile and 
colon cancer risk, and confers the benefit of physicians recommending appropriate 
screenings for the individual as well as at-risk family members. The identification and 
increased screening of high-risk individuals enhances the diagnosis and prevention of 
colon cancer thereby reducing mortality due to the disease.  
 
The objectives of the Familial Colorectal Cancer Registry are to: 1) establish a family 
registry for colorectal cancer studies, 2) collect biological specimens from affected 
individuals and their close relatives, 3) determine the impact of genetic counseling 
and molecular diagnostics on colorectal cancer detection and prevention, and 4) 
evaluate risk factors and develop strategies for clinical intervention for individuals at 
high risk of developing colorectal cancer.  
 
Since 1996 the Registry has expanded to include individuals with familial and 
inherited patterns of colorectal cancer as well as those diagnosed with colorectal 
cancer before the age of 55. As of October 1998, approximately 100 individuals have 
agreed to participate in the Registry. For more information about the Registry, please 
call Deborah Rose at 215-955-0026.  
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